Biodyne Co., Ltd.
Financials
Valuation Metrics
Biodyne Co., Ltd.'s Market Cap is ₩1833B. At end of 2025 it was ₩4018B. Ranked #846 of 2,405 in KR market (top 35%), #385 of 1,627 on KOSDAQ (top 24%), #27 of 94 in Health Care Equipment & Services (top 29%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 183.35B KRW | KR#846/2,405 Sec#27/94 |
| Revenue | 5.77B KRW | KR#2,314/2,405 Sec#84/94 |
| Net Income | 1.22B KRW | KR#1,462/2,405 Sec#46/94 |
| Total Assets | 44.94B KRW | KR#2,238/2,405 Sec#78/94 |
| Net Assets | 44.07B KRW | KR#1,982/2,405 Sec#66/94 |
| Employees | 19 | KR#2,240/2,405 Sec#89/94 |
| Value | ||
| P/E | 149.94x | KR#1,513/2,405 Sec#48/94 |
| P/B | 4.16x | KR#2,215/2,405 Sec#85/94 |
| P/S | 31.75x | KR#2,350/2,405 Sec#91/94 |
| EV/EBITDA | 2208.69x | KR#1,566/2,405 Sec#51/94 |
| FCF Yield | -1.42% | KR—/2,405 Sec—/94 |
| Profitability | ||
| ROE | 2.77% | KR#1,340/2,405 Sec#47/94 |
| ROA | 2.72% | KR#1,086/2,405 Sec#42/94 |
| Op. Margin | 1.34% | KR#1,463/2,405 Sec#49/94 |
| Revenue Growth | 2.36% | KR#1,353/2,405 Sec#68/94 |
| Financial Health | ||
| Debt Ratio | 1.98% | KR#8/2,405 Sec#1/94 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/94 |
| FCF | -2.60B KRW | KR#1,367/2,405 Sec#45/94 |
| Cash | 12.98B KRW | KR#1,537/2,405 Sec#46/94 |
| Current Ratio | 45.95x | KR#6/2,405 Sec#1/94 |
| Performance | ||
| 1Y Return | -55.52% | KR#2,067/2,405 Sec#78/94 |
| 1M Return | -9.81% | KR#1,144/2,405 Sec#44/94 |
| From 52W High | -63.46% | KR#1,816/2,405 Sec#63/94 |
| 1Y MDD | -64.93% | KR#1,710/2,405 Sec#61/94 |
| Trading | ||
| Volume | 39,038 shares | KR#1,120/2,405 Sec#38/94 |
| Trading Value | 233.5M KRW | KR#1,067/2,405 Sec#39/94 |
| Foreign Own. | 4.32% | KR#976/2,405 Sec#31/94 |
| Per Share | ||
| EPS | 41 KRW | KR#1,510/2,405 Sec#48/94 |
| BPS | 1,481 KRW | KR#2,203/2,405 Sec#81/94 |
Company Info
Established in 2013, the company develops, manufactures, and sells liquid-based cytology equipment and cancer diagnostic reagent kits, completing a special listing on the KOSDAQ market in 2021. It exports its independently developed blowing technology-based LBC equipment, 'PATHPLORER', and reagent kits to 13 countries, securing patents in multiple nations. The company has an exclusive license agreement with Roche for slide smearing device development, planning to unveil 'VENTANA SP400' in Japan in 2025 and pursue global sales. Biodine is headquartered in Seongdong-gu, Seoul.